新冠疫苗緊急使用年齡范圍擴大到3歲以上

國務院聯(lián)防聯(lián)控機制科研攻關組相關負責人表示，國家已批準將新冠疫苗緊急使用年齡范圍擴大到3歲以上。

China is expected to administer COVID-19 vaccinesto at least 70 percent of the target population by the end of this year, an official from the National Health Commission confirmed, as the country continues to rampup its inoculationdrive to approve the emergency use of COVID-19 vaccines for those agedbetween 3 and 17 years old.

我國繼續(xù)推進新冠疫苗接種工作，已批準將3-17歲人群納入新冠疫苗緊急使用年齡范圍。國家衛(wèi)健委相關負責人表示，預計到今年年底前，我國將完成至少70%的目標人群接種。

Preliminary results from Phase I and II clinical trials showed the vaccinecould trigger immune response in three to 17 year-old participants, and most adversereactions were mild.

Ⅰ/Ⅱ期臨床試驗初步結果顯示，疫苗能夠觸發(fā)3到17歲接種者體內的免疫反應，多數(shù)不良反應輕微。

Following approval by relevant authorities, vaccinationwill be open to people in this age group based on the epidemicprevention and control situation .

經(jīng)國家有關部門批準后，會根據(jù)疫情防控需要在這一人群中推動接種。

年齡最大接種者超過100歲

Over 763 million doses of COVID-19 vaccines had been administered across China as of Saturday, NHC figures showed.

國家衛(wèi)健委發(fā)布的數(shù)據(jù)顯示，截至6月5日，我國新冠疫苗接種已超過7.63億劑次。

The oldest vaccine recipientsin China's vaccination campaign, open to people aged over 18, are more than 100 years old.

目前我國新冠疫苗接種面向18歲以上人群，其中年齡最大的接種者超過100歲。

China is also making headway in creating nasal spray and inhaledCOVID-19 vaccines as clinical trials of them are underway, and experts will study their safety and efficacy after completing the collection of relevant data.

我國在鼻噴霧式 / 吸入型新冠疫苗研發(fā)方面也有新進展，目前這種疫苗正在進行臨床試驗。相關數(shù)據(jù)收集完成后，專家將對其安全性和有效性展開研究。